Novartis has proposed Dr. Giovanni Caforio, ex-CEO and Executive Chairman of Bristol Myers Squibb, as Chair of the company’s Board of Directors. 

The election to decide the next chair of Novartis’ Board of Directors will take place at the company’s next Annual General Meeting in 2025, when current Chair Dr. Joerg Reinhardt ends his 12-year tenure, as scheduled in 2025, when he will retire and not be available for re-election at the Annual General Meeting.  

Dr. Reinhardt joined Sandoz in 1982 and has held managerial positions with increasing responsibility in Sandoz and thereafter Novartis, including Head of the Vaccines and Diagnostics Division and Chief Operating Officer. In 2013, he was appointed Chair of the Board of Directors.  

From May 2015 to November 2023, Dr. Caforio was CEO of BMS, and from May 2017 to March 2024, he served as Executive Chairman. He joined BMS in 2000 and served in various senior roles at the company, 

Source: Novartis